Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer Backs Eylea's Prospects Despite Lucentis Biosimilars

Market leader In Wet AMD Still Selling Strongly

Executive Summary

Competition, both branded and generic, is on the rise but the German group believes that Eylea will continue to outperform given its safety and efficacy profile and the potential of a longer-lasting version of the eye therapy.

You may also be interested in...



Coherus Shrugs Off Missing Ranibizumab Pre-Filled Syringe – For Now

Coherus BioSciences had much to say during its second-quarter earnings call in the wake of USFDA approval for its Bioeq-partnered Cimerli biosimilar to Roche’s Lucentis.

Coherus Shakes Up Ranibizumab Competition With First Interchangeable US Biosimilar

Coherus BioSciences has heralded a “strategic inflection point” for the company after receiving USFDA approval for Cimerli as an interchangeable biosimilar rival to Lucentis. The firm has also revealed launch plans for the Bioeq-partnered ranibizumab product.

Roche Is ‘Aiming For The Sky’ With Vabysmo Commercial Launch

CEO Severin Schwan compared his enthusiasm for the newly launched eye drug to Ocrevus, the company's top-selling drug.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146840

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel